Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Drug Resistance, Neoplasm
  • Genes, erbB-1
  • Lung Neoplasms
  • Quinazolines

abstract

  • The presence of sensitizing EGFR mutations correlates with radiographic response. A short course of preoperative treatment serves a platform for evaluating activity of new agents and assures sufficient tumor availability for correlative analyses.

publication date

  • May 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3261615

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-2102

PubMed ID

  • 21558399

Additional Document Info

start page

  • 3500

end page

  • 6

volume

  • 17

number

  • 10